Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01006018 · ClinicalTrials.gov registry record · NA
DPP-4 Inhibition and TZD for DM Prevention
A NA study, sponsored by Emory University.
- Terminated
- Registry status
- NA
- Development phase
- 3
- Enrollment target
NCT01006018 is a NA study that was terminated before completion, run by Emory University. The registered enrollment target is 3 participants.
The verdict
NCT01006018, a NA study, was terminated before completion, sponsored by Emory University.
- TERMINATED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
Study Summary
To determine whether treatment with the diabetes medication, Januvia (sitagliptin), with or without another diabetes medicine, Actos (pioglitazone), will improve insulin secretion and insulin response individuals with Impaired Glucose Tolerance (IGT), a form of prediabetes.
Interventions
- DRUG PLACEBO
- DRUG Sitagliptin + Pioglitazone PLACEBO
- DRUG Sitagliptin + Pioglitazone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2011-07 |
| Est. Completion | 2011-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01006018
The ClinicalTrials.gov registry entry for NCT01006018 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which PLACEBO is the first listed.
NCT01006018 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01006018 about?
NCT01006018 is a clinical study titled "DPP-4 Inhibition and TZD for DM Prevention". To determine whether treatment with the diabetes medication, Januvia (sitagliptin), with or without another diabetes medicine, Actos (pioglitazone), will improve insulin secretion and insulin response individuals with Impaired Glucose Tolerance (IGT), a form of prediabetes.
What is the current status of trial NCT01006018?
This trial is currently terminated. It is a NA study. The enrollment target is 3 participants. The study started on 2011-07. Estimated completion is 2011-12.
What interventions are being tested in trial NCT01006018?
The interventions under investigation include: PLACEBO (DRUG), Sitagliptin + Pioglitazone PLACEBO (DRUG), Sitagliptin + Pioglitazone (DRUG).
Who is sponsoring clinical trial NCT01006018?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.